Visit DiaPharma IN PERSON at the SOT 61st Annual Meeting and ToxExpo

Posted: March 10, 2022

It’s Not Just Support. It’s Solutions.

Mechanistic Biomarkers

Increased Organ Specificity DILI DIKI

Visit booth 1118 to learn about our extensive line of mechanistic biomarker assays for drug safety studies. Our knowledgeable scientists are happy to discuss liver and kidney injury biomarkers for early DILI/DIKI prediction, featuring Keratin 18 (K18/CK18).

K18 biomarkers have improved organ specificity over traditional biomarkers. Our K18 M30 Apoptosense® and M65® ELISAs detect apoptosis and/or necrosis whether caused by drugs, toxins, or disease.

Learn about our extensive line of biomarker assays for detecting safety signals in drug development, including osteopontin, L-FABP, ╬▒-GST, NGAL, and Cystatin C.

For research use only. Not for use in diagnostic procedures.


  • Increased organ specific serum biomarker
  • Quantifies hepatocyte cell death to assess liver toxicity
  • Low day-to-day fluctuation and remarkably stable in serum
  • Convenient ready-to-use ELISA format

It’s Not Just Support. It’s Solutions.

Celebrating 25 years of scientific expertise, with support just a call or click away.

diapharma bioassays hemostasis thrombosis chromogenic


DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069

Technical Support: 1.800.447.3846